← Back to Search

Topical Retinoid and Benzoyl Peroxide Combination

IDP-126 Gel for Acne Vulgaris

Phase 2
Waitlist Available
Research Sponsored by Bausch Health Americas, Inc.
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial
Must have
Timeline
Screening 3 weeks
Treatment Varies
Follow Up baseline to week 12

Summary

This trial tests the safety and effectiveness of IDP 126 Gel, a daily skin treatment, on patients aged 12 and older with moderate to severe acne. The gel likely works by reducing inflammation, killing bacteria, and clearing blocked pores.

Eligible Conditions
  • Acne Vulgaris
  • Acne

Timeline

Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~baseline to week 12
This trial's timeline: 3 weeks for screening, Varies for treatment, and baseline to week 12 for reporting.

Treatment Details

Study Objectives

Study objectives can provide a clearer picture of what you can expect from a treatment.
Primary study objectives
Percentage of subjects who achieve at least a two-grade reduction from baseline and are "Clear" or "Almost Clear" at Week 12 in the Evaluator's Global Severity Score.

Side effects data

From 2021 Phase 3 trial • 183 Patients • NCT04214639
12%
Application site pain
7%
Erythema
100%
80%
60%
40%
20%
0%
Study treatment Arm
IDP-126 Gel
IDP-126 Vehicle Gel

Trial Design

3Treatment groups
Experimental Treatment
Active Control
Placebo Group
Group I: IDP-126 GelExperimental Treatment1 Intervention
Group II: Epiduo® Forte GelActive Control1 Intervention
Group III: IDP-126 Vehicle GelPlacebo Group1 Intervention
Treatment
First Studied
Drug Approval Stage
How many patients have taken this drug
IDP-126 Gel
2020
Completed Phase 3
~1860

Find a Location

Who is running the clinical trial?

Bausch Health Americas, Inc.Lead Sponsor
262 Previous Clinical Trials
81,244 Total Patients Enrolled
23 Trials studying Acne Vulgaris
7,825 Patients Enrolled for Acne Vulgaris
Anya LoncaricStudy DirectorBausch Health Americas, Inc.
39 Previous Clinical Trials
19,977 Total Patients Enrolled
11 Trials studying Acne Vulgaris
4,566 Patients Enrolled for Acne Vulgaris
Varsha BhattStudy DirectorBausch Health Americas, Inc.
8 Previous Clinical Trials
353 Total Patients Enrolled
~155 spots leftby Dec 2025
Unbiased ResultsWe believe in providing patients with all the options.
Your Data Stays Your DataWe only share your information with the clinical trials you're trying to access.
Verified Trials OnlyAll of our trials are run by licensed doctors, researchers, and healthcare companies.
Back to top